Compare OMH & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | GTBP |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 13.0M |
| IPO Year | 2022 | 2016 |
| Metric | OMH | GTBP |
|---|---|---|
| Price | $2.42 | $7.04 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.5M | 350.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.22 |
| 52 Week High | $3.75 | $8.82 |
| Indicator | OMH | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 70.84 |
| Support Level | $0.89 | $0.36 |
| Resistance Level | $3.75 | N/A |
| Average True Range (ATR) | 0.25 | 0.91 |
| MACD | -0.01 | 0.89 |
| Stochastic Oscillator | 60.40 | 66.49 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, Digital Marketing Services, and emerging and other services. The firm operates in two segments, which are Brokerage, emerging and another related service; and Estate management services and other related services in Singapore.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.